For those investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Leerink representative.

Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation into the Clinic With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus ...

Remix Therapeutics WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA ...